RNSs14 May 2021 12:36
We are LONG overdue news - everyone knows this already. So I thought I'd have a scour of the last year's RNSs to see the frequency of meaningful updates. Excluding all the clutter (Price Monitorings, Voting Rights, Exercise of Options, AGMs, etc) so we distil down to the key messages about progress. This is what we get:
May 2020 = 3. Placing/Broker, Patent Filing, Covid update
June = 0
July = 1. Work Programme & Strategic Update
Aug = 1. Positive Covid In-Vitro Study
Sept = 3. Tech Transfer & M'fact, Covid PoC Update, Interim Results
Oct = 0
Nov = 2. Operational Update, Nuvec/Oncology launch
Dec = 2. Formulation work update, £2M Placing
2021
Jan = 0
Feb = 2. Intention to Grant Patent, Final Results
Mar = 0
Apr = 0
May = 0
It's been a long silence recently and work - we must assume - is continuing behind the scenes. My post isn't intended to criticise, just to point out that something's increasingly likely to land soon. As a reminder of what may come in the next few months:
Oncology - Stage 2 of the programme expected to conclude in Autumn (up to 12 months from Nov 2020)
Nuvec in-vivo - due to commence early in 2021 (did I miss announcement of it starting ?)
Patent - full grant should take 6-8 months (started in Feb, so due in early autumn)
Nanomerics - 14 month research collaboration started Feb 2020 (so expired April 2021 ???). Announcement could be imminent on renewing Nanomerics agreement, or new research partner
But for me the prime suspect for news would be the collaboration discussions with potential licensing partners. It may be that there's a cluster of positive news around study results of dispersion, followed by licensing as new study data reassures partners of Nuvec's safety and efficacy. That would make the 2020/21 SP range insignificant. You'd have to be talking 30-50p on news of one partner (depending on terms).
Anyway, as we know, news can land at any time. Good luck all.